Zalcitabine ( DrugBank: Zalcitabine )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 25 | 進行性多巣性白質脳症 | 1 |
25. 進行性多巣性白質脳症
臨床試験数 : 26 / 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001048 (ClinicalTrials.gov) | February 1998 | 2/11/1999 | Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients | A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected Subjects | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Filgrastim;Drug: Cytarabine;Drug: Zidovudine;Drug: Zalcitabine;Drug: Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | Bristol-Myers Squibb;Upjohn | Completed | 18 Years | 65 Years | All | 90 | Phase 2 | United States |